Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1

Clinical trial NCT06767514 · RECRUITING

Trial details

NCT number: NCT06767514
Sponsor: Summit Therapeutics
Status: RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Non-Small Cell Lung Cancer

Start date: 2025-02-27
Primary completion: 2028-04-01
Enrollment: 780

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.